



ASX ANNOUNCEMENT

31 August 2018

Cynata to Present at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City

Melbourne, Australia; 30 August 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) announced today that Dr Ross Macdonald, Managing Director and CEO, will present a company overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Thursday, September 6, at 12:05 p.m. EDT at the St. Regis New York in New York City.

Dr Macdonald will provide an update on Cynata and its unique Cymerus™ therapeutic mesenchymal stem cell (MSC) technology platform, with a particular emphasis on the positive results of the Phase 1 clinical trial of its lead therapy CYP-001 for the treatment of graft-versus-host disease (GvHD).

Cynata will also participate in one-on-one meetings with U.S. and international investors and potential partners who are registered to attend. Over 2,000 institutional and other investors are expected to attend the conference, each with a significant interest in the life sciences sector.

For additional information on the conference, please visit rodmanevents.com.

Ends

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Alex Liddington-Cox, Australia Media Contact, +61 (0)474701469, alex.liddingtoncox@mcpartners.com.au
Laura Bagby, U.S. Media Contact, 312-448-8098, lbagby@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus utilises induced pluripotent stem cells (iPSCs) to produce a particular type of MSC precursor, called a mesenchymoangioblast (MCA). Cymerus provides a source of MSCs that is independent of donor limitations and an "off-the-shelf" stem cell platform for therapeutic product use, with a pharmaceutical product business model and economies of scale. This has the potential to create a new standard in the emergent arena of stem cell therapeutics, and provides both a unique differentiator and an important competitive position.